PB1877: ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC LYMPHOCYTIC LEUKEMIA

• P. Gaitonde,
• B. Liljas,
• B. Shaw,
• P. Miranda

Affiliations

P. Gaitonde

1 AstraZeneca, Gaithersburg, United States of America

B. Liljas

1 AstraZeneca, Gaithersburg, United States of America

B. Shaw

2 AstraZeneca, Cambridge, United Kingdom

P. Miranda

1 AstraZeneca, Gaithersburg, United States of America